These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 30285769)

  • 1. Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1.
    Lin A; Balazs AB
    Retrovirology; 2018 Oct; 15(1):66. PubMed ID: 30285769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus.
    Ahmad M; Ahmed OM; Schnepp B; Johnson PR
    Annu Rev Virol; 2017 Sep; 4(1):491-510. PubMed ID: 28645240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention.
    Brady JM; Baltimore D; Balazs AB
    Immunol Rev; 2017 Jan; 275(1):324-333. PubMed ID: 28133808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adeno-Associated Viral Vector Mediated Expression of Broadly- Neutralizing Antibodies Against HIV-Hitting a Fast-Moving Target.
    Sherpa C; Le Grice SFJ
    Curr HIV Res; 2020; 18(2):114-131. PubMed ID: 32039686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention.
    Thavarajah JJ; Hønge BL; Wejse CM
    Viruses; 2024 Jun; 16(6):. PubMed ID: 38932203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis.
    Phelps M; Balazs AB
    Front Immunol; 2021; 12():734304. PubMed ID: 34603314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice.
    Wu X; Guo J; Niu M; An M; Liu L; Wang H; Jin X; Zhang Q; Lam KS; Wu T; Wang H; Wang Q; Du Y; Li J; Cheng L; Tang HY; Shang H; Zhang L; Zhou P; Chen Z
    J Clin Invest; 2018 Jun; 128(6):2239-2251. PubMed ID: 29461979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promise and Progress of an HIV-1 Cure by Adeno-Associated Virus Vector Delivery of Anti-HIV-1 Biologics.
    Gardner MR
    Front Cell Infect Microbiol; 2020; 10():176. PubMed ID: 32391289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives.
    Mahomed S
    Clin Microbiol Rev; 2024 Jun; 37(2):e0015222. PubMed ID: 38687039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review.
    Mahomed S; Garrett N; Baxter C; Abdool Karim Q; Abdool Karim SS
    J Infect Dis; 2021 Feb; 223(3):370-380. PubMed ID: 32604408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple Combinations of AAV9-Vectors Encoding Anti-HIV bNAbs Provide Long-Term In Vivo Expression of Human IgG Effectively Neutralizing Pseudoviruses from HIV-1 Global Panel.
    Shipulin GA; Glazkova DV; Urusov FA; Belugin BV; Dontsova V; Panova AV; Borisova AA; Tsyganova GM; Bogoslovskaya EV
    Viruses; 2024 Aug; 16(8):. PubMed ID: 39205270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broadly Neutralizing Antibodies for HIV-1 Prevention.
    Walsh SR; Seaman MS
    Front Immunol; 2021; 12():712122. PubMed ID: 34354713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibodies for HIV-1 prevention.
    Julg B; Barouch DH
    Curr Opin HIV AIDS; 2019 Jul; 14(4):318-324. PubMed ID: 31082819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-based protection against HIV infection by vectored immunoprophylaxis.
    Balazs AB; Chen J; Hong CM; Rao DS; Yang L; Baltimore D
    Nature; 2011 Nov; 481(7379):81-4. PubMed ID: 22139420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.
    Wagh K; Seaman MS; Zingg M; Fitzsimons T; Barouch DH; Burton DR; Connors M; Ho DD; Mascola JR; Nussenzweig MC; Ravetch J; Gautam R; Martin MA; Montefiori DC; Korber B
    PLoS Pathog; 2018 Mar; 14(3):e1006860. PubMed ID: 29505593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Report of the 2014 Cent Gardes HIV Vaccine Conference - Part 1: Neutralizing Antibodies; Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 October 2014.
    Girard MP; Picot V; Longuet C; Nabel GJ
    Vaccine; 2015 Jul; 33(31):3605-8. PubMed ID: 25769208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention.
    Stephenson KE; Wagh K; Korber B; Barouch DH
    Annu Rev Immunol; 2020 Apr; 38():673-703. PubMed ID: 32340576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application.
    Ding C; Patel D; Ma Y; Mann JFS; Wu J; Gao Y
    Front Immunol; 2021; 12():697683. PubMed ID: 34354709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.
    Zhang Z; Li S; Gu Y; Xia N
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broadly neutralizing antibodies targeting HIV: Progress and challenges.
    Paneerselvam N; Khan A; Lawson BR
    Clin Immunol; 2023 Dec; 257():109809. PubMed ID: 37852345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.